Trevi Therapeutics, Inc. TRVI

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

Seeking Alpha · 2026-08-20

Trevi starts a chronic-cough trial for ~2–3M U.S. patients

Stock Titan · 2026-08-06

TRVI Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Trevi Therapeutics (TRVI) Institutional Ownership 2026 $TRVI

MarketBeat · 2026-08-20

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

Yahoo Finance · 2026-07-17

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire · 2026-05-05

Trevi Therapeutics, Inc. (TRVI) Stock Report: Strong Buy Ratings Signal 42% Upside Potential

DirectorsTalk Interviews · 2026-07-31

Why Trevi Therapeutics (TRVI) Stock Is Up Today

Quiver Quantitative · 2026-07-17

Trevi Therapeutics (TRVI) Stock May Be Overvalued Despite Its 5 Year Surge

simplywall.st · 2026-07-17

TRVI Stock Firms Up As Haduvio Story Hits Center Stage

StocksToTrade · 2026-07-17

Trevi Therapeutics stock hits all-time high at 19.33 USD

Investing.com · 2026-07-07

FMR LLC discloses 8.8% Trevi Therapeutics (TRVI) ownership in amended 13G

Stock Titan · 2026-08-06

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Yahoo Finance · 2026-04-16

Trevi Therapeutics Announces Upcoming June and July Event Schedule

GlobeNewswire · 2026-06-17

Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside

TradingView · 2026-08-07

Show 10 more ↓

Upstream Bio, Inc. (UPB) UPB Neuphoria Therapeutics Inc. (NEUP) NEUP Nuvation Bio Inc. (NUVB) NUVB BELITE BIO, INC (BLTE) BLTE Travere Therapeutics, Inc. (TVTX) TVTX